Global Markets Direct’s, 'Microalbuminuria - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Microalbuminuria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Microalbuminuria. Microalbuminuria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Microalbuminuria. - A review of the Microalbuminuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Microalbuminuria pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Microalbuminuria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Microalbuminuria pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Microalbuminuria - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Microalbuminuria Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Microalbuminuria 6 Microalbuminuria Therapeutics under Development by Companies 8 Mid Clinical Stage Products 9 Comparative Analysis 9 Early Clinical Stage Products 10 Comparative Analysis 10 Microalbuminuria Therapeutics - Products under Development by Companies 11 Companies Involved in Microalbuminuria Therapeutics Development 12 Bristol-Myers Squibb Company 12 FibroGen, Inc. 13 Microalbuminuria - Therapeutics Assessment 14 Assessment by Monotherapy Products 14 Assessment by Route of Administration 15 Assessment by Molecule Type 17 Drug Profiles 19 FG-3019 - Drug Profile 19 Product Description 19 Mechanism of Action 19 RandD Progress 19 BMS-813160 - Drug Profile 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 Microalbuminuria Therapeutics - Drug Profile Updates 22 Microalbuminuria Therapeutics - Discontinued Products 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables
Number of Products Under Development for Microalbuminuria, H1 2013 6 Products under Development for Microalbuminuria - Comparative Analysis, H1 2013 7 Number of Products under Development by Companies, H1 2013 8 Comparative Analysis by Mid Clinical Stage Development, H1 2013 9 Comparative Analysis by Early Clinical Stage Development, H1 2013 10 Products under Development by Companies, H1 2013 11 Bristol-Myers Squibb Company, H1 2013 12 FibroGen, Inc., H1 2013 13 Assessment by Monotherapy Products, H1 2013 14 Assessment by Stage and Route of Administration, H1 2013 16 Assessment by Stage and Molecule Type, H1 2013 18 Microalbuminuria Therapeutics - Drug Profile Updates 22 Microalbuminuria Therapeutics - Discontinued Products 24
List of Figures
Number of Products under Development for Microalbuminuria, H1 2013 6 Products under Development for Microalbuminuria - Comparative Analysis, H1 2013 7 Products under Development by Companies, H1 2013 8 Mid Clinical Stage Products, H1 2013 9 Early Clinical Stage Products, H1 2013 10 Assessment by Monotherapy Products, H1 2013 14 Assessment by Route of Administration, H1 2013 15 Assessment by Stage and Route of Administration, H1 2013 16 Assessment by Molecule Type, H1 2013 17 Assessment by Stage and Molecule Type, H1 2013 18